Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hopefully someone here looked up chtp
PR,
Pay close att. to chtp next month NDA.
End of the year FDA approval......good chance at least.
Good luck with health.
Pete Rose
I hope you doing OK.
Do you still own pphm?
Rusty, The mgmt, pushed Da merger trough. Shorts will be forced to cover. ROSG scenario for BPAX?????? Short living spike is coming!!
I'm wondering how is our Friend Pete doing?
I hope he is OK.
Mgmt. has one more week to swing/ attract/ motivate the SH to vote their way. For me cancellation of RS would do the trick JMO.
If their greed for golden parachutes is a major concern? why wouldn't they just play along and remove the damn thing from Da merger?
The other option replace the g. parachutes with CVR's for Insiders, if they honestly believe in LibiG and ANI future why not to prove it this way. Lost credibility is very hard to regain back.
Whatever Mgmt is doing now? most of SH don't trust it.
Professor, good move!!! I'm glad to see you here.
I'm not sure if that's what is going on?
Didn't they confirm Jan 17 as a day of record?
If they could buy the votes they would, no doubt.
They still need millions votes, with that kind of volume we have lately, it would take months to get what they need.
Has anybody else been called by BPAX Rep?
I stated to the Lady not to call me again,
The only way I will change my decision? BETTER MERGER TERMS,
or New Deal.
Apparently still not enough votes.
Two more weeks to present new deal or modified ANI one.
GL to all, especially Pete
Pete, until today I stopped posting here.
It is just sad what is going on. Sorry for what happened to you guys.
BPAX cronies will call you for voting, The lady is doing her job.
I did not vote, and I don't plan to vote unless the situation will change.
I think and hope BOD wont get what they are looking for.
SH had it!!!!!!!!
Mgt. still does not want to understand THEY HAVE TO DO RIGHT or this miserable POS is history.
Just curious????
How come they call from my local area code 201?????
It must be the drones!!!!!!!!
They keep calling for the votes!!!!!!
My response!!!!!!!!!!!!!!!! I AM NOT VOTING AT ALL!!!!!!!
Until they change the merger terms!!!!!!!!! AMEN!!!!!!!!!!!!!!
Pete, I FEEL VERY SORRY FOR YOU!!!!!!
I hope you gonna be OK!!!!!!
Win
Rusty, are you a Funny Girls union guy?
BTW, BPAX mgt. may have a good reason for that RS.
I don't believe this crap!!!!
Short Interest down a bit : 3/15/2013 2,926,302,
The lowest level after last R/S.
Well, they are getting ready for re-entry following 3rd R/S.
People remember another Wall street darling GNTA?
BPAX has the same smell.
We invested for LibiG, GVAX, John Hopkins......
Big expectations ended up in the dumpster.
Now we hope some left overs will leak from the bottom....
so we can lick it to compensate hopes.
Trading basically died, It is not in BPAX interest for shares to change hands at this point, we can be sure they wont put out any news until merger.
They will work on present SH to cave in.
I DO NOT VOTE FOR ANY CRAPPY OPTIONS, NOT AT ALL.
Well, at least they won something.....
2 FDA approved drugs, I don't even want to think how "Great" they will do with another one approved.
Still some People want to give them a benefit of doubt.
Still don't realize BOD and CEO Simes are the wolves in human skin.
To complete their destructive mission and rape SH with GRANDE FINALE they want Da ANI merger, letting them off the hook and collecting golden parachutes benefits. They should end up behind the bars instead.
Rusty, Safety study is still blinded, they said $10M to analyze teh study. Supposedly is OK?????
Efficacy failed year ago. Remember???
New 2 studies were recommended by FDA each about 18M.
they would run for 6 months
BioSante Pharmaceuticals, Inc. Sends Letter Urging Stockholders to Vote “FOR” Proposed Merger with ANI Pharmaceuticals, Inc. 03/19 09:00 AM
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (BPAX:$1.29,00$-0.01,00-0.77%) today sent a letter to stockholders in connection with its proposed merger with ANI Pharmaceuticals, Inc. recommending that BioSante stockholders vote “FOR” the proposed merger. The letter highlights the significant benefits to BioSante stockholders of the value of the proposed merger and the importance of promptly delivering a vote “FOR” the merger.
The full text of the letter follows:
March 19, 2013
Dear Fellow Stockholder:
Last Friday March 15, 2013, BioSante adjourned until April 12, 2013 its special meeting of stockholders to vote on the proposed merger of BioSante with ANI Pharmaceuticals, Inc. The votes received to date have been voted overwhelmingly in favor of the merger. We believe that most of you recognize the benefits of our proposed merger with ANI. We are concerned, however, that many of you may not realize how important your individual vote is to approving the merger.
We encourage all BioSante stockholders to read the definitive joint proxy statement/prospectus for a detailed discussion of ANI, the proposed merger, the merger agreement and the process that led to the proposed merger. In addition, we have prepared the following answers to the most common questions posed by BioSante stockholders regarding the proposed merger and stockholder vote:
Why does it make sense for BioSante to merge?
The BioSante board of directors strongly believes that the proposed merger with ANI is the best alternative for BioSante stockholders. If the merger isn’t approved, BioSante will remain a stand-alone company and will still need to address the issues and risks that led it to propose the merger with ANI in the first place. The BioSante board of directors believes that the merger would create more value for BioSante stockholders in the long-term than BioSante could create as an independent, stand-alone company.
BioSante solely on its own has expended significant time and resources with respect to LibiGel®. However, LibiGel® cannot be marketed or sold until FDA approval is obtained and the efficacy data collected in BioSante’s two efficacy trials and its safety study are not adequate to enable BioSante to seek or obtain that approval. BioSante would need substantial additional funding to conduct the needed additional efficacy trials.
Why merge with ANI?
ANI is led by a highly experienced management team focused on revenue growth and profitability. By commercializing a variety of branded and generic products, ANI reduces risk for the company and its stockholders. ANI owns two pharmaceutical manufacturing plants which enable management to control costs and compete more effectively. These plants have specialized capabilities which allow ANI to focus on developing niche products with fewer competitors.
Although other merger proposals were entertained by BioSante prior to entering into the merger agreement with ANI, the BioSante board of directors believes that the merger with ANI is the best option for BioSante stockholders.
Why did the BioSante board of directors adjourn the stockholders’ meeting to give stockholders more time to vote?
Over 60% of BioSante’s shares weren’t voted at all on the merger. Since the average BioSante stockholder owns about 750 shares, every stockholder’s vote counts, including yours.
Why should I bother to vote for the merger?
You should vote in favor of the merger because it is the best alternative available for BioSante stockholders. You will retain a right to benefit from LibiGel®, both through contingent value rights (CVRs), and through your ownership in the merged company. At the same time, you will have an ownership interest in ANI.
The BioSante board of directors has determined that the merger is in the best interests of the BioSante stockholders and unanimously recommends that BioSante stockholders vote “FOR” the merger.BioSante strongly encourages ALL stockholders to vote their shares for the merger by calling (800) 357-9167.Each BioSante stockholder’s vote is critical to the success of the merger whether the position be 100,000 shares or 100 shares.
This call should take less than one minute. No confidential information will be required. The BioSante board of directors unanimously recommends that stockholders vote “FOR” the adoption of the merger agreement and all related matters being submitted to a vote of BioSante stockholders.
Three leading independent proxy advisory firms, ISS Proxy Advisory Services, Glass, Lewis & Co. and Egan-Jones Proxy Services, have recommended votes FOR the merger. None of these recommendations was solicited by BioSante or ANI, and no fees were paid by BioSante or ANI to any of these companies.
The special meeting has been adjourned to give BioSante stockholders additional but limited time to consider the merger proposal and to VOTE PROMPTLY their shares. In addition to calling 800-357-9167, you also may vote in one of the following ways:
Over the phone, by calling 1-800-690-6903 and using touch tone to deliver voting instructions (note that you will need your control number on your proxy card)
Via the Internet at www.proxyvote.com (note that you will need your control number on your proxy card)
By mail, by promptly returning your enclosed proxy card.
If your broker has asked you for voting instructions on the merger proposal and you have not responded or failed to deliver instructions to your broker on how it should vote your shares, your failure to give instructions is the same as a vote “AGAINST” the merger. The BioSante board of directors urges you to promptly return voting instructions to your broker or promptly vote “FOR” the merger proposal by calling 1-800-690-6903 or going online at www.proxyvote.com or returning your completed proxy card.Alternatively, you may call (800) 357-9167 to vote your shares.
The Proposed BioSante/ANI Merger is the Best Alternative for BioSante Stockholders
The proposed merger of BioSante and ANI is the best alternative for BioSante stockholders.If holders of a majority of BioSante common stock do not vote “FOR” the merger proposal, BioSante will remain a stand-alone company and will need to address the same financial and strategic issues and risks that led it to propose the merger with ANI.
Upon completion of the merger, the combined company will be renamed ANI Pharmaceuticals, Inc. and will operate under the leadership of the ANI management team, with Arthur S. Przybyl serving as president and chief executive officer. Mr. Przybyl has expressed to us the strong belief of the entire ANI management team that by merging with BioSante it can create value for all stockholders. We and they believe that the combined strengths of our two companies will be a powerful accelerant to growth.
The BioSante board of directors URGES you to vote promptly “FOR” the proposed merger. The time needed to vote is short and you can provide your vote easily by phone, over the Internet or by mail. If you have received a request for voting instructions from your broker, we urge you promptly to provide those instructions-- if you do not, it is the same as a vote “AGAINST” the proposed merger. The new voting deadline is midnight, Eastern Time, on April 11, 2013.
On behalf of your board of directors, we thank you for your continued support.
Sincerely,
/s/ Louis W. Sullivan, M.D.
Chairman of the Board
BioSante stockholders who need assistance in voting their shares or who have questions regarding BioSante’s special meeting may contact The BioSante Proxy Information Line toll-free at (800) 357-9167 or AST Phoenix Advisors at (877) 478-5038 (international stockholders, please call (201) 806-7323).
About the Proposed Merger
Under the terms of the merger agreement, if the proposed merger is completed, ANI will merge with and into BioSante, with BioSante continuing as the surviving company. The combined company that will result from the merger will be a fully integrated specialty branded and generic pharmaceutical company focused on developing, manufacturing and marketing branded and generic prescription pharmaceuticals. BioSante and ANI both believe that the merger of the two companies will be able to create more value than either company could achieve individually.
BioSante stockholders are encouraged to read the definitive joint proxy statement/prospectus as it provides, among other things, a detailed discussion of ANI, the proposed merger, the merger agreement and the process that led to the proposed merger.
Forward-Looking Statements
To the extent any statements made in this communication deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the proposed merger between BioSante and ANI, the terms, timing, conditions to and anticipated completion of the proposed merger, BioSante’s anticipated net cash and the anticipated ownership of the combined company, the composition of the combined company’s board of directors and management team; the anticipated distribution to BioSante stockholders of contingent value rights (CVRs) immediately prior to the merger and the terms, timing and value of such CVRs, the potential benefits of the proposed transaction to the BioSante and ANI stockholders, the combined company’s plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of the combined company and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante’s and the combined company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include, among others, the failure of the BioSante stockholders to approve the transaction, the risk that BioSante’s net cash will be lower than currently anticipated or the failure of either party to meet the other conditions to the closing of the transaction; delays in completing the transaction and the risk that the transaction may not be completed at all; the failure to realize the anticipated benefits from the transaction or delay in realization thereof; the businesses of BioSante and ANI may not be combined successfully, or such combination may take longer, be more difficult, time-consuming or costly to accomplish than expected; operating costs and business disruption during the pendency of and following the transaction, including adverse effects on employee retention and on business relationships with third parties; the risk that the CVRs may not be paid out or result in any value to BioSante’s stockholders; general business and economic conditions; the combined company’s need for and ability to obtain additional financing; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante’s and the combined company’s licensees or sublicensees.More detailed information on these and additional factors that could affect BioSante´s actual results are described in BioSante´s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K.All forward-looking statements in this news release speak only as of the date of this news release and are based on BioSante´s current beliefs and expectations. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Important Additional Information for Investors and Stockholders
This communication is being made in respect of the proposed merger between BioSante and ANI and related matters involving BioSante and ANI. In connection with the proposed transaction, BioSante has filed with the SEC and the SEC has declared effective a registration statement on Form S-4, containing a joint proxy statement/prospectus and other relevant materials. The final definitive joint proxy statement/prospectus has been sent to the stockholders of BioSante and ANI. Investors and security holders are urged to read the joint proxy statement/prospectus (including any amendments or supplements) and other documents filed with the SEC carefully in their entirety because they contain important information about BioSante, ANI and the proposed transaction.
Investors and security holders may obtain free copies of the registration statement and the joint proxy statement/prospectus and other documents filed with the SEC by BioSante at the SEC’s web site at www.sec.gov. Free copies of the registration statement and the joint proxy statement/prospectus and other documents filed with the SEC also can be obtained by directing a request to BioSante, Attention: Investor Relations, telephone: (847) 478-0500. In addition, investors and security holders may access copies of the documents filed with the SEC by BioSante on BioSante’s website at www.biosantepharma.com.
BioSante and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction described in this release. Information regarding BioSante’s directors and executive officers is available in BioSante’s annual report on Form 10-K for the year ended December 31, 2012, which was filed with the SEC on February 28, 2013. Investors and stockholders can obtain more detailed information regarding the direct and indirect interests of BioSante’s directors and executive officers in the proposed transaction by reading the definitive joint proxy statement/prospectus.
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Source: BioSante Pharmaceuticals, Inc. (BPAX:$1.29,00$-0.01,00-0.77%)
Get more news on:SYMBOLS: BPAXNEWS TYPE: Corporate Events, Corporate Events: Mergers and Acquisitions, Top News, Top Stories: InvestingSECTORS: Health Care, Pharmaceuticals
Any vote you cast, it will be counted to the overall volume.
Once they get over 50 % of OS voted then yes or no will matter.
In that case they will have YES advantage.
At this point not voting at all is the way to go if you against the terms of merger.
Someone's point out that majority of shares is owned by retail people who held over previews RS's and are so much under water they don't even care to vote anymore makes sense.
For these SH BPAX PPS would stage some major move to activate them again.
Just the prospect of another RS induce resentment and more anger against this "capable BOD" and CEO getting ready to strap golden parachutes. I don't blame SH at all.
Jadite, remember, 1:4 R/S will put total OS at about 6M.
New Mgmt will burn new cash in no time, we know that.
Guess what next step is goin to be? Dilution..... As always they will play with SH minds. They will find dozens of different "great" reasons to justify Issuing of what?.... 6, 7, 8 Millions of new shares....off course for the best of SH!!!!!!
So R/S will cut your position then new shares will possible dilute value of SH positions by half.
And frankly I don't buy this theoretical argument that RS doesn't dilute. Look BPAX history of two RS.
BPAX Share Holders won this battle, how can we win the war?
All your findings an posts I find very important.
Mgmt. seems to be determent to push Da merger trough.
Their plan is in motion, some events already took place.
We lost GVAX, work force is in reduction process, Dr. Snubes is out.
I wont be surprise with another shoe to drop any day now, I'm sure they have next step preplanned.
The wracking ball is in full swing.
Adjournment of Friday's SH meet was something that BOD of both Companies didn't expect to happen.
I assume they never expected this kind of resistance to Da merger Idea.
I admit I have not voted at all.
The simple reason, I can't find enough evidence so far to make any kind of sensible decision. I'm not gonna vote for something unknown to find out what's in it. If not voting is the best way to go? so be it. Maybe it's sounds pathetic that's OK.
This whole BPAX story makes me sick.
BioSante Pharmaceuticals Announces Adjournment of Its Stockholders Meeting Until April 12, 2013
BioSante Announces Approval and Declaration of Contingent Value Rights Distribution 03/15 04:05 PM
ANI Announces Approval of Merger by Its Stockholders
LINCOLNSHIRE, Ill. & BAUDETTE, Minn.--(BUSINESS WIRE)-- BioSante Pharmaceuticals, Inc. (BPAX:$1.30,00$0.02,001.56%) and ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. announced today that ANI stockholders have approved the merger of ANI into BioSante, and that BioSante has adjourned its stockholders meeting until April 12, 2013 to give BioSante stockholders additional time to vote.
A majority of all outstanding shares of BioSante stock must vote in favor for the merger to occur. As of March 15, 2013, 33% of the outstanding shares have been voted in favor of the merger, which is short of the required majority. Of those shares that have been voted on the merger, 84% have been voted in favor. A total of approximately 15 million shares, however, have not been voted at all with respect to the merger.
BioSante strongly encourages ALL stockholders to vote their shares for the merger by calling (800) 357-9167.Each BioSante stockholder’s vote is critical to the success of the merger whether the position be 100,000 shares or 100 shares.
This call should take less than one minute. No confidential information will be required. The board of directors of BioSante unanimously recommends that stockholders vote “FOR” the adoption of the merger agreement and all related matters being submitted to a vote of BioSante stockholders.
Dr. Louis W. Sullivan, chairman of the board of BioSante stated, “The votes received to date have been voted overwhelmingly in favor of the merger with ANI. We believe that most BioSante stockholders recognize the benefits of our proposed merger with ANI. We are concerned, however, that many of them may not realize how important their individual votes are to approving the merger. The board of directors of BioSante unanimously approved this merger and we continue to believe strongly that it is very much in the best interest of our stockholders from a financial perspective.”
“In view of the vital importance of the merger to BioSante and its stockholders, the board of directors of BioSante concluded it was appropriate to adjourn the meeting and extend the voting period to allow BioSante stockholders the opportunity to vote,” said Dr. Sullivan, chairman of the board of BioSante.
Upon completion of the merger, the combined company will be renamed ANI Pharmaceuticals, Inc. and will operate under the leadership of the ANI management team, with Arthur S. Przybyl serving as president and chief executive officer.
“The entire ANI management team strongly believes that by merging with BioSante we can create value for all stockholders,” said Mr. Przybyl. “The combined strengths of our two companies will be a powerful accelerant to growth.”
BioSante also announced today that its board of directors has declared the distribution of contingent value rights (CVRs) providing payment rights arising from a future sale, transfer, license or similar transaction(s) involving BioSante’s LibiGel® (female testosterone gel) to holders of BioSante common stock and set the close of business on April 12, 2013, the date of the adjourned special meeting of BioSante stockholders, as the record date with respect to such distribution. The CVR distribution will be effected immediately prior to, but contingent upon, completion of the merger.
The special meeting of BioSante stockholders will be reconvened at 8:00 a.m., Central Time, on April 12, 2013 at BioSante’s corporate office located at 111 Barclay Boulevard, Lincolnshire, Illinois 60069. BioSante stockholders are encouraged to read the definitive joint proxy statement/prospectus as it provides, among other things, a detailed discussion of the proposed merger, the merger agreement and the process that led to the proposed merger.
The record date for the BioSante stockholders entitled to vote at the special meeting remains January 17, 2013. Stockholders who already have given a proxy or instructions to brokers do not need to re-cast their votes.
If the BioSante stockholders approve the merger, it is expected that the merger will close as soon as practicable thereafter.
BioSante stockholders are reminded that their vote is important.A failure to vote has the same effect as a vote against the adoption of the merger agreement.Any BioSante stockholder who has not yet voted is urged to vote FOR the adoption of the merger agreement and the transactions contemplated thereby, as well as the other merger related proposals.BioSante stockholders who need assistance in voting their shares or who have questions regarding BioSante’s special meeting may contact The BioSante Proxy Information Line toll-free at (800) 357-9167 or AST Phoenix Advisors at (877) 478-5038 (international stockholders, please call +1(201) 806-7323).
About the Proposed Merger
Under the terms of the merger agreement, if the proposed merger is completed, ANI will merge with and into BioSante, with BioSante continuing as the surviving company. The combined company that will result from the merger will be a fully integrated specialty branded and generic pharmaceutical company focused on developing, manufacturing and marketing branded and generic prescription pharmaceuticals. BioSante and ANI both believe that the merger of the two companies will be able to create significantly more value than either company could achieve individually.
BioSante stockholders are encouraged to read the definitive joint proxy statement/prospectus as it provides, among other things, a detailed discussion of ANI, the proposed merger, the merger agreement and the process that led to the proposed merger.
Forward-Looking Statements
To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the proposed merger between BioSante and ANI, the terms, timing, conditions to and anticipated completion of the proposed merger, BioSante’s anticipated net cash and the anticipated ownership of the combined company, the composition of the combined company’s board of directors and management team; the anticipated distribution to BioSante stockholders of contingent value rights (CVRs) immediately prior to the merger and the terms, timing and value of such CVRs, the potential benefits of the proposed transaction to the BioSante and ANI stockholders, the combined company’s plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of the combined company and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante’s and the combined company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include, among others, the failure of the BioSante stockholders to approve the transaction, the risk that BioSante’s net cash will be lower than currently anticipated or the failure of either party to meet the other conditions to the closing of the transaction; delays in completing the transaction and the risk that the transaction may not be completed at all; the failure to realize the anticipated benefits from the transaction or delay in realization thereof; the businesses of BioSante and ANI may not be combined successfully, or such combination may take longer, be more difficult, time-consuming or costly to accomplish than expected; operating costs and business disruption during the pendency of and following the transaction, including adverse effects on employee retention and on business relationships with third parties; the risk that the CVRs may not be paid out or result in any value to BioSante’s stockholders; general business and economic conditions; the combined company’s need for and ability to obtain additional financing; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante’s and the combined company’s licensees or sublicensees.More detailed information on these and additional factors that could affect BioSante´s actual results are described in BioSante´s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K. All forward-looking statements in this news release speak only as of the date of this news release and are based on BioSante´s current beliefs and expectations. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Important Additional Information for Investors and Stockholders
This communication is being made in respect of the proposed merger between BioSante and ANI and related matters involving BioSante and ANI. In connection with the proposed transaction, BioSante has filed with the SEC and the SEC has declared effective a registration statement on Form S-4, containing a joint proxy statement/prospectus and other relevant materials. The final definitive joint proxy statement/prospectus has been sent to the stockholders of BioSante and ANI. Investors and security holders are urged to read the joint proxy statement/prospectus (including any amendments or supplements) and other documents filed with the SEC carefully in their entirety because they contain important information about BioSante, ANI and the proposed transaction.
Investors and security holders may obtain free copies of the registration statement and the joint proxy statement/prospectus and other documents filed with the SEC by BioSante at the SEC’s web site at www.sec.gov. Free copies of the registration statement and the joint proxy statement/prospectus and other documents filed with the SEC also can be obtained by directing a request to BioSante, Attention: Investor Relations, telephone: (847) 478-0500. In addition, investors and security holders may access copies of the documents filed with the SEC by BioSante on BioSante’s website at www.biosantepharma.com.
BioSante and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction described in this release. Information regarding BioSante’s directors and executive officers is available in BioSante’s annual report on Form 10-K for the year ended December 31, 2012, which was filed with the SEC on February 28, 2013. Investors and stockholders can obtain more detailed information regarding the direct and indirect interests of BioSante’s directors and executive officers in the proposed transaction by reading the definitive joint proxy statement/prospectus.
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130315005809/en/
Source: BioSante Pharmaceuticals, Inc. (BPAX:$1.30,00$0.02,001.56%)
Get more news on:SYMBOLS: BPAXNEWS TYPE: Corporate Events, Corporate Events: Mergers and Acquisitions, Top News, Top Stories: InvestingSECTORS: Health Care, Pharmaceuticals
Pete Mgt. is in denial for long time, right now they are still scratching their heads, what went wrong.
I have new ticker recommendation....HASH
better yet HUSH HUSH.........
Pete, yo breaking my heart ;-o
what do we save with NO golden parachutes......?
If it's true Wow!!!! Are they folding ???? BPAX size the operations?
I guess only BOD wil stay to the end to strap on the golden parachutes and sail away?
One interesting data from Yahoo BPAX profile
Count of employees 23 down from 54
HS what make SO SURE?????? I'm very interested, give me one think...
Just one solid think.
Yahoo Board in key stats shows truly creative picture of BPAX
For ex. MC $115M !!!!! SO 89M Revenue $2.3 M / $.11 per share????
Math at its best, truly reliable source of DD!!!!!.
I guess whoever was crunching the numbers for BPAX got new job at Yahoo?????
This is pathetic.
Pete, isn't this ironic that GVAX got dumped at the same price?
I was trying to make a point how screwed up the BPAX portfolio valuation is. Piece of equipment build I don't know by bunch of Chinese workers? at the same price as Cancer study portfolio of 17 vaccines? Are we a bunch of morons to believe that?
I don't think so.
Pete, What about that Gel filling machine?
If they let GVAX go for $1 mil, while paid $ 9 Mil for it.
I'm seriously interested how much Mgt. wants for that baby?
Maybe first $90k will take it?
Pete NYC is a busy place, Ice cream stand equipped in this kind of Hi-tech machinery would make a fortune. I told you once about it. Remember?
Maybe Catty could recommend perfect location?
As a little start up production outfit we could use BPAX NASDAQ listing down the road to hit the big world. ;-0
Jeff, it is obvious for me al this manipulation has one goal.
Conditioning the BPAX SH to vote YES. For merger.
With the Misery Index at the worst level we are having almost no choice in their opinion .
Just imagine if all the the points you are making would have positive answers? How ANI a little production Company would fit into this picture. The merging parties plus Oppenheimer leveled the playing field down to make this somehow work.
Then the "Best" of it BIOSANTE is a surviving company put in minority merger.
Pete CC call is ON rigth now
Pete, watching our other dog?
PW, thank you.
Could someone , post PPHM CC webcast link?
Thanks
It looks like this MB has more then 200 followers.
We have only few pretty active Posters. The sentiment is pretty strong against some of the terms of The Merger Agreement.
NOT THE WHOLE IDEA OF THE ANI MERGER.
We have just 3 more days left to SH Meet.
To show to Mgt. the BPAX SH position it's time for this MB NOT to go silent, quite contrary let's speak up!!!!!!!
Going into the meeting on Friday CEO Simes, BOD, ANI CEO Przybyl ANI BOD they need to have clear signal what BPAX SH are looking for.
That we want the Merger to be modified, to become fair for BPAX SH.
Common R3D, I'm as pissed of as you are, for me JTFM is genuine in his efforts. As I told him once.....maybe him and all of us we're looking for gold in wrong place. Maybe there is no gold here and it never was. JMO
SEC gets new "Sheriff"
http://finance.yahoo.com/news/sec-nominee-white-promises-unrelenting-025101980.html
White built a reputation as a hard-nosed Manhattan federal prosecutor before moving into private practice for the past 10 years, defending major Wall Street figures, including JPMorgan and former Bank of America Chief Executive Kenneth Lewis.
In pledging to aggressively go after individuals who violate the law, White appeared to be getting out in front of critical questions she will likely face on Tuesday, both on the SEC's record and her recent defense work.
Some think if one has a title, degree in front of name, somehow that person is better, deserves trust and respect, in most cases that could be true. Beware of white collar crooks. Count your fingers after you shake hands.
If all these Dr's are so Noble. why for heaven sake, are they all jumping the ship with golden parachutes, leaving us with CVR rescue rafts locked up in safe? ......sorry folks we not sure if they are inflated.